Research landscape

GLP-1 and obesity: where to start a cited external-science review

This public snapshot helps a team identify the records, institutions, and subtopics to inspect first. It is not a trial landscape, competitive ranking, clinical recommendation, or commercial conclusion.

Source scope: 599 recent NLM PubMed records from 2021 through 2026 matching a GLP-1 and obesity query. Generated July 2026.

Signals in this retrieved set

SignalWhat it means
599 recent recordsA bounded public starting set, not complete coverage of every publication, trial, company, or asset.
GLP-1 receptor agonists: 66The most frequent indexed subtopic in this retrieval.
Semaglutide: 56A frequent indexed term in the same retrieval.
Tirzepatide: 31A frequent indexed term in the same retrieval.

Useful first questions

Which records should the team open first? Which institutions recur in the retrieved authorship? Which indexed subtopics dominate the current public set? Which additional sources are needed before making a clinical, partnering, or market decision?

Representative public records

PMID 42477216 · Recent public GLP-1 and obesity record.

PMID 42475086 · Recent public GLP-1 and obesity record.

PMID 42474946 · Recent public GLP-1 and obesity record.

The linked records are representative of the retrieved set. Their presence does not establish quality, suitability, availability, safety, efficacy, or business value.

Limits

Author names are not disambiguated, counts are not citation-weighted, affiliation labels can be abbreviated, and a recent PubMed search is not a systematic review. Review the linked primary records and add the required clinical, patent, trial, regulatory, and company sources before acting.

Continue with your exact topic

Run the live preview Inspect the KOL map Request a free mini-brief